Context Therapeutics Statistics
Total Valuation
CNTX has a market cap or net worth of $245.32 million. The enterprise value is $174.84 million.
Important Dates
The next estimated earnings date is Wednesday, May 6, 2026, after market close.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CNTX has 91.88 million shares outstanding. The number of shares has increased by 62.94% in one year.
| Current Share Class | 91.88M |
| Shares Outstanding | 91.88M |
| Shares Change (YoY) | +62.94% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 1.36% |
| Owned by Institutions (%) | 24.39% |
| Float | 42.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.98 |
| P/TBV Ratio | 3.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.52, with a Debt / Equity ratio of 0.00.
| Current Ratio | 8.52 |
| Quick Ratio | 8.23 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -46.39% and return on invested capital (ROIC) is -31.80%.
| Return on Equity (ROE) | -46.39% |
| Return on Assets (ROA) | -29.79% |
| Return on Invested Capital (ROIC) | -31.80% |
| Return on Capital Employed (ROCE) | -65.65% |
| Weighted Average Cost of Capital (WACC) | 15.07% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.01M |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +336.28% in the last 52 weeks. The beta is 1.97, so CNTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.97 |
| 52-Week Price Change | +336.28% |
| 50-Day Moving Average | 2.53 |
| 200-Day Moving Average | 1.39 |
| Relative Strength Index (RSI) | 49.47 |
| Average Volume (20 Days) | 954,088 |
Short Selling Information
The latest short interest is 1.29 million, so 1.40% of the outstanding shares have been sold short.
| Short Interest | 1.29M |
| Short Previous Month | 1.15M |
| Short % of Shares Out | 1.40% |
| Short % of Float | 3.02% |
| Short Ratio (days to cover) | 1.38 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -39.70M |
| Pretax Income | -36.12M |
| Net Income | -36.12M |
| EBITDA | -39.69M |
| EBIT | -39.70M |
| Earnings Per Share (EPS) | -$0.38 |
Full Income Statement Balance Sheet
The company has $66.00 million in cash and $112,064 in debt, with a net cash position of $65.88 million or $0.72 per share.
| Cash & Cash Equivalents | 66.00M |
| Total Debt | 112,064 |
| Net Cash | 65.88M |
| Net Cash Per Share | $0.72 |
| Equity (Book Value) | 60.47M |
| Book Value Per Share | 0.66 |
| Working Capital | 60.33M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$26.39 million and capital expenditures -$33,948, giving a free cash flow of -$26.42 million.
| Operating Cash Flow | -26.39M |
| Capital Expenditures | -33,948 |
| Depreciation & Amortization | 16,251 |
| Net Borrowing | n/a |
| Free Cash Flow | -26.42M |
| FCF Per Share | -$0.29 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CNTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -62.94% |
| Shareholder Yield | -62.94% |
| Earnings Yield | -15.01% |
| FCF Yield | -10.97% |
Analyst Forecast
The average price target for CNTX is $6.60, which is 147.19% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.60 |
| Price Target Difference | 147.19% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |